Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disease Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLPTM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLPTM1 Extracellular Loop (ECD) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CLPTM1 Products |
| Gene Delivery | CLPTM1 Lentivirus Premade Particles Full-length ORF for stable cell line construction and cell-based assays. |
View CLPTM1 Products |
| Benchmark Ab | Anti-CLPTM1 Recombinant Antibody High-affinity sequence-verified clone for positive control and FACS/IHC validation. |
View CLPTM1 Products |
| Validator | CLPTM1 siRNA Set Target-specific knockdown pool for functional assay validation. |
View CLPTM1 Products |
| Related Target A | CLPTM1L (CLPTM1-Like) Highly homologous family member implicated in cisplatin resistance and pan-cancer survival pathways. |
View CLPTM1L Products |
| Related Target B | GABRA1 (GABA-A Receptor Alpha 1) Direct functional interactor; CLPTM1 modulates GABA-A receptor trafficking and synaptic plasticity. |
View GABRA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Target Integrity | Lentivirus-driven stable cell line expression preserving native multi-pass conformation. |
| Off-Target Screening vs CLPTM1L | High-purity recombinant CLPTM1L proteins available for cross-reactivity and specificity panels. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives | Highly specific siRNA validation sets included to confirm target-dependent phenotypes. |
Live CLPTM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic exploration of CLPTM1 (Cleft Lip and Palate Transmembrane Protein 1) is gaining momentum as researchers uncover its dual role in oncology and neurobiology. Originally identified in developmental biology, CLPTM1 is now recognized as a critical modulator of GABA-A receptor trafficking and a driver of tumor progression in non-small cell lung cancer (NSCLC) and glioblastoma. The race for CLPTM1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted small molecules and cell-based modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the CLPTM1-GABA receptor interface and downstream PI3K/AKT signaling cascades.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Academic Institutions, Biotech Startups | Solid Tumors (NSCLC, Glioblastoma) | Conformational target binding (Need Lentivirus for cell-based FACS screening) |
| Small Molecule Inhibitors | Oncology-focused Biopharma | GABA-A-related Neurological Disorders | Functional modulation assays (Need GABRA1 co-expression models) |
| siRNA / RNAi | RNA Therapeutics Specialists | Refractory Cancers | Target knockdown and downstream signaling validation (Need validated siRNA sets) |